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Abstract: Purpose: Evaluation of long-term outcome and toxicity of moderately hypofractionated radio-
therapy using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost treatment
planning and cone beam CT-based image guidance for localized prostate cancer. Methods: Between 2005
and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy using
cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modu-
lated arc therapy (IG-VMAT) with a simultaneous integrated boost (SIB). Total doses of 73.9 Gy (n =
44) and 76.2 Gy (n = 302) to the high-dose PTV were delivered in 32 and 33 fractions, respectively. The
low-dose PTV received a dose (D95) of 60.06 Gy in single doses of 1.82 Gy. The pelvic lymph nodes were
treated in 91 high-risk patients to 45.5 Gy (D95). Results: Median follow-up was 61.8 months. The 5‑year
biochemical relapse-free survival (bRFS) was 85.4% for all patients and 93.3, 87.4, and 79.4% for low-,
intermediate-, and high-risk disease, respectively. The 5‑year prostate cancer-specific survival (PSS) was
94.8% for all patients and 98.7, 98.9, 89.3% for low-, intermediate-, and high-risk disease, respectively.
The 5‑year and 10-year overall survival rates were 83.8 and 66.3% and the 5‑year and 10-year freedom
from distant metastasis rates were 92.2 and 88.0%, respectively. Cumulative 5‑year late GU toxicity and
late GI toxicity grade ฀2 was observed in 26.3 and 12.1% of the patients, respectively. Cumulative 5‑year
late grade 3 GU/GI toxicity occurred in 4.0/1.2%. Conclusion: Moderately hypofractionated radiother-
apy using SIB treatment planning and cone beam CT image guidance resulted in high biochemical control
and survival with low rates of late toxicity.
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Abstract
Purpose Evaluation of long-term outcome and toxicity of moderately hypofractionated radiotherapy using intensity-modu-
lated radiotherapy (IMRT) with simultaneous integrated boost treatment planning and cone beam CT-based image guidance
for localized prostate cancer.
Methods Between 2005 and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy
using cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modulated arc
therapy (IG-VMAT) with a simultaneous integrated boost (SIB). Total doses of 73.9Gy (n= 44) and 76.2Gy (n= 302)
to the high-dose PTV were delivered in 32 and 33 fractions, respectively. The low-dose PTV received a dose (D95) of
60.06Gy in single doses of 1.82Gy. The pelvic lymph nodes were treated in 91 high-risk patients to 45.5Gy (D95).
Results Median follow-up was 61.8 months. The 5-year biochemical relapse-free survival (bRFS) was 85.4% for all patients
and 93.3, 87.4, and 79.4% for low-, intermediate-, and high-risk disease, respectively. The 5-year prostate cancer-specific
survival (PSS) was 94.8% for all patients and 98.7, 98.9, 89.3% for low-, intermediate-, and high-risk disease, respectively.
The 5-year and 10-year overall survival rates were 83.8 and 66.3% and the 5-year and 10-year freedom from distant
metastasis rates were 92.2 and 88.0%, respectively. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥2
was observed in 26.3 and 12.1% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in
4.0/1.2%.
Conclusion Moderately hypofractionated radiotherapy using SIB treatment planning and cone beam CT image guidance
resulted in high biochemical control and survival with low rates of late toxicity.
Keywords Simultaneous integrated boost · Cone beam CT · Hypofractionation · Intensity-modulated radiation therapy ·
Image-guided radiation therapy
Introduction
Primary radiotherapy as an established curative treatment
option for localized prostate cancer, one of the most com-
mon cancer types [1], has undergone substantial changes in
clinical practice. Lately, hypofractionated [2–7] and dose-
escalated [8–10] approaches are on the advance to improve
the therapeutic ratio, reduce cost, and shorten the duration
of prostate radiation therapy.
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When on-board cone beam CT (CBCT) became available
in 2004, highly conformal image-guided intensity-modu-
lated radiation therapy (IG-IMRT) made dose-escalated ra-
diotherapy with reduced target volume margins a viable
option. As one of the first centers worldwide to imple-
ment CBCT-based IG-IMRT, we postulated that by adopt-
ing a combination of CBCT, IG-IMRT with simultaneous
integrated boost (SIB), tight margins, and hypofractionated
dose-escalated radiotherapy, high biochemical control with
reduction of gastrointestinal toxicity would be achievable.
In an earlier publication, the outcome and toxicity data
of the first treated patients were reported [11] but limited
long-term data are available for moderately hypofraction-
ated dose-escalated CBCT-based image-guided IMRT with
simultaneous integrated boost (SIB). In this publication,





This updated analysis is based on 346 consecutive pa-
tients treated between 2005 and 2015 with moderately
hypofractionated intensity-modulated CBCT-based image-
guided radiotherapy for localized prostate cancer. All pa-
tients had pathologically confirmed prostate cancer with
risk stratification according to D’Amico et al.
As published before, radiotherapy was delivered with
IG-IMRT or IG-VMAT in 33 fractions with SIB and two
dose levels of 1.82 and 2.31Gy per fraction, resulting in
a prescribed PTV dose of 60.06Gy (D95) and a PTVBoost
mean dose of 76.23Gy. 32 fractions were applied only in
patients with low-risk prostate cancer in 44 cases. For pelvic
lymphatic radiation, the prescribed dose was 45.5Gy (D95)
with 1.82Gy per fraction. A CTVP–SV was generated con-
sisting of the prostate and the base of the seminal vesicles,
whereas CTVP+SV included the prostate and the seminal
vesicles. PTVBoost was defined by a 5-mm margin around
CTVP–SV with avoidance of the rectum. The PTV was cre-
ated by a 10-mm margin around CTVP+SV in all but the
dorsal direction, where a 7-mm margin was used. Pinnacle3
Table 1 Patient and treatment characteristics
Characteristic All
N = 346 (100%)
Prostate only
N = 255 (73.7%)
Prostate+ pelvic LN
N = 91 (26.3%)
Age, median (range) in years 73 (47–84) 73 (47–83) 72 (52–84)
KPS, median (range) in % 90 (60–100) 90 (70–100) 90 (60–100)
iPSA, median (range) in ng/ml 8.4 (0.1–434.8) 6.7 (0.1–434.8) 24.8 (3.2–334)
Gleason score
≤6 120 (34.7%) 114 (44.7%) 6 (6.6%)
7 142 (41.0%) 111 (43.5%) 31 (34.1%)
8–10 80 (23.1%) 27 (10.6%) 53 (58.2%)
N/A 4 (1.2%) 3 (1.2%) 1 (1.1%)
T stage
T1 228 (65.9%) 180 (70.6%) 48 (52.7%)
T2 78 (22.5%) 57 (22.4%) 21 (23.1%)
T3 32 (9.2%) 15 (5.9%) 17 (18.7%)
T4 6 (1.7%) 2 (0.8%) 4 (4.4%)
N/A 2 (0.6%) 1 (0.4%) 1 (1.1%)
D’Amico risk group
Low risk 78 (22.5%) 78 (30.6%) 0 (0.0%)
Intermediate risk 122 (35.3%) 117 (45.9%) 5 (5.5%)
High risk 142 (41.0%) 57 (22.4%) 85 (93.4%)
N/A 4 (1.2%) 3 (1.2%) 1 (1.1%)
Androgen deprivation
Low risk 13/78 (16.7%) 13/78 (16.7%) 0 (0.0%)
Intermediate risk 34/122 (27.9%) 32/117 (27.4%) 2/5 (40.0%)
High risk 104/142 (73.2%) 33/57 (57.9%) 71/85 (83.5%)
N/A 4/346 (1.2%) 3/255 (1.2%) 1/91 (1.1%)
KPS Karnofsky score; LN lymph nodes; N/A not available; iPSA initial prostate-specific antigen
(Philips Radiation Oncology Systems, Fitchburg, WI, USA)
was used for treatment planning. More information on tar-
get volume definition, treatment planning, and treatment
delivery has been described before [11, 12].
Physician-recorded toxicity and biochemical control
were assessed prospectively. Biochemical failure was de-
fined according the Phoenix definition as nadir plus an
increase of ≥2ng/ml in prostate-specific antigen (PSA).
Androgen deprivation therapy was recommended for pa-
tients with intermediate- (6 months) and high-risk disease
(24–36 months) and prescribed at the discretion of the treat-
ing urologist. Assessment of toxicity during radiotherapy
was performed every 2 weeks until the end of treatment,
6 weeks after treatment, and in 6-month intervals there-
after. Two years after treatment, follow-up continued yearly.
Gastrointestinal (GI) and genitourinary (GU) toxicity was
scored using Common Terminology Criteria for Adverse
Events (CTCAE) v4.0. Toxicity data of the earlier patient
group from 2005 to 2010 was retrospectively reclassi-
fied from CTCAE v3.0 to v4.0 to achieve comparability.
Acute toxicity was defined as occurring within 3 months
after radiotherapy. Late toxicity assessment included the




Biochemical relapse-free survival, overall survival, prostate
cancer-specific survival, and freedom from distant metas-
tasis were calculated using the Kaplan–Meier method and
log-rank tests were applied for analysis. For the comparison
of toxicity of prostate only versus prostate and pelvic lymph
node radiotherapy one-sided Fisher’s exact tests were per-
formed. Statistical analysis was conducted using IBM SPSS
v.25.0 (IBM Corp., Armonk, NY, USA). Differences were
considered statistically significant in case of p< 0.05.
Fig. 1 Gastrointestinal toxic-
ity. Shown is the time course
of physician-recorded gastroin-
testinal toxicity according to
CTCAE v4.0. RT radiotherapy,
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Fig. 2 Genitourinary toxicity.
Shown is the time course of
physician-recorded genitouri-
nary toxicity according to CT-
CAE v4.0. RT radiotherapy,
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Results
The reviewed 346 male patients had a median age of 73
(range 47–84) years and a median Karnofsky score of 90%.
In reference to the risk classification of D’Amico 78, 122
and 142 patients had low-, intermediate-, and high- risk
prostate cancer, respectively. Clinical characteristics are
summarized in Table 1.
The time course of GI toxicity is shown in Fig. 1.
No grade 4 toxicities were observed and 4 patients in
total developed late grade 3 (1.2%) GI toxicity cumu-
lated over 5-year follow-up: 3 patients developed late
rectal bleeding (mean 22.0± 15 months after radiotherapy,
10.0± 3.5 months duration) and 1 patient developed late
K
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fecal incontinence (48 months after radiotherapy, chronic);
1 patient with late rectal bleedings additionally suffered
from proctitis grade 3. The maximum of acute GI toxicity
occurred 6 weeks after the start of radiotherapy and de-
creased fast thereafter. Late grade 2 GI toxicity peaked at
the 60-month follow-up and normalized thereafter. Over-
all, acute GI toxicity grade ≥2 was observed in 13.0% of
patients and cumulative 5-year late GI toxicity grade ≥2 in
12.1% of all patients.
The time course of GU toxicity is presented in Fig. 2. No
grade 4 toxicities were observed. After 5 years of follow-up,
14 patients (4.0%) developed late grade 3 GU toxicity: 5 pa-
tients developed late grade 3 macroscopic hematuria (mean
25.2± 14.9 months after radiotherapy, 12.0± 0.0 months du-
ration; two chronic cases); 8 patients suffered from late
grade 3 urinary incontinence (mean 31.5± 13.9 months af-
ter radiotherapy, 20.0± 15.0 months duration; two chronic
cases); 1 patient developed late grade 3 non-infective cysti-
tis (36 months after radiotherapy, chronic). The maximum
of acute GU toxicity occurred 6 weeks after the start of
radiotherapy and decreased significantly within 6 weeks.
GU toxicity was increased in patients with pelvic node ir-
radiation: cumulative 5-year late grade ≥2 GU toxicity was
observed in 23.5% of patients in the group of prostate only
radiotherapy and 34.1% of the patients with prostate and
Fig. 3 Biochemical relapse-free survival. Shown is the biochemical relapse-free survival according to risk group for the low-risk group (A),
intermediate-risk group (B), and high-risk group (C), with the comparison of low-risk versus high-risk (p= 0.026, log-rank test)
pelvic lymph node irradiation (p= 0.036, one-sided Fisher’s
exact test). Late grade 2 to 3 toxicity showed a peak at the
36-month follow-up and decreased after the 60-month fol-
low-up. Overall acute GU toxicity grade ≥2 was observed
in 30.1% and cumulative 5-year late GU toxicity grade ≥2
in 26.3% of all patients.
Median follow-up was 61.8 (range 0.5–147.3) months.
The 5-year biochemical relapse-free survival (bRFS) was
85.4% for all patients and 93.3, 87.4, and 79.4% for low-,
intermediate-, and high-risk disease (Fig. 3). For high-risk
patients 5-year bRFS was 90.9% with androgen depriva-
tion therapy and 55.4% without (p= 0.008, Fig. 4). For the
cohort of intermediate-risk patients androgen deprivation
therapy did not significantly influence bRFS.
The 5-year prostate-specific survival (PSS) was 94.8%
for all patients and 98.7, 98.9, and 89.3% for low-, interme-
diate-, and high-risk disease, respectively. 10-year prostate-
specific survival was 92.4%. The 5- and 10-year overall
survival rates were 83.8 and 66.3%, respectively.
During follow-up 27 patients developed distant metasta-
sis, resulting in 5- and 10-year freedom from distant metas-
tasis rates of 92.2 and 88%, respectively. 5-year freedom
from distant metastasis was 98.7, 95.5, and 87.0% for low-,
intermediate-, and high-risk disease, respectively (Fig. 5).
K
Strahlenther Onkol
Fig. 4 Biochemical relapse-free survival in high-risk patients with or without androgen deprivation therapy. Shown is the biochemical relapse-free
survival with (A) and without (B) androgen deprivation therapy for the high-risk group (p= 0.008; log-rank test). ADT androgen deprivation therapy
Androgen deprivation therapy did not significantly influ-
ence freedom from distant metastasis in any risk group.
Discussion
Recent meta-analyses indicate that hypofractionated ra-
diotherapy is non-inferior to conventional radiotherapy in
terms of tumor control [13–15], but may suffer from an
increased risk of toxicity [14, 16]. We report a “real world”
cohort from a single institution. Strengths are the uniform
manner of target contouring, dose prescription, and IMRT
realization, as well as strict CBCT-based image guidance.
The variable use of additive androgen deprivation and
pelvic node irradiation in about 25% of patients with an
assumed higher risk of lymph node metastasis introduces
some heterogeneity which is difficult to classify.
In our patient cohort the 5-year prostate-specific survival/
biochemical relapse-free survival of 94.8/85.4% for all pa-
tients and the 5-year bRFS of 79.4% in the high-risk group
support the high efficiency of dose-escalated hypofraction-
ated primary radiotherapy with SIB for prostate cancer. As-
suming a dose–effect relationship [17, 18], this result may
in part be explained by the dose prescription of 33-times
1.82/2.31Gy. With an assumed α/β ratio of 1.5 or 2.7Gy,
this corresponds to a mean PTVBoost EQD2 dose of 83 or
81Gy, respectively. The EQD2 of 81 Gy2.7 in our study ex-
ceeded other recent trials of moderately hypofractionated
radiotherapy like the CHHIP [2], PROFIT [19] (73 Gy2.7),
and RTOG [4] (77 Gy2.7) trials, while the HYPRO [20]
trial used a higher EQD2 (84 Gy2.7). Our outcome data
are comparable to the trials mentioned above. For exam-
ple, the CHHIP trial reported a 5-year bRFS of 90.6% and
the PROFIT trial of 85%. While bRFS was superior in the
CHHIP trial, the relative number of high-risk patients was
lower than in our own patient cohort (12% vs. 41%) [2, 20].
Interestingly, for the subgroup of high-risk patients in our
cohort, the 5-year bRFS was significantly increased with an-
drogen deprivation therapy (ADT; 5-year bRFS 90.9% vs.
55.4%, p= 0.008), which clearly underlines the importance
of ADT in the high-risk group [21, 22], despite treatment
with escalated radiotherapy doses. In contrast, the sequence
of ADT and radiotherapy appears to be less important [23].
Short-term androgen deprivation was part of the treatment
protocol in the CHHIP trial; it was excluded in the PROFIT
trial, which included only patients with intermediate risk.
In our cohort no influence of androgen deprivation ther-
apy on bRFS could be observed in the intermediate-risk
group. Further improvements in biochemical control can be
achieved by standardized androgen deprivation therapy at
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Fig. 5 Freedom from distant metastasis. Shown is freedom from distant metastasis for the low-risk group (A), intermediate-risk group (B), and
high-risk group (C), with the comparison of low-risk vs. high-risk group (p= 0.003, log-rank test)
least in the high-risk group. Prescription of ADT in our
patients was at the discretion of the treating urologist and
only 73.2% of our high-risk cancer patients received ADT.
Patient preference and comorbidities were considered in the
decision-making process for or against ADT.
We electively irradiated the pelvic lymph nodes in pa-
tients with an estimated risk of lymph node involvement
greater than 15% (according to the Roach formula) [24].
Even though evidence for prophylactic pelvic lymph node
irradiation is sparse and the GETUG-01 study observed no
improvement of event-free survival after a median follow-
up of 11.4 years [25], the RTOG 9413 trial showed im-
proved progression-free survival with pelvic lymph node
radiation treatment [26]. Therefore, pelvic lymph node ir-
radiation may have contributed to biochemical control in
high-risk patients.
This report differs from other studies, as a simultaneous
integrated boost was used and the high-dose PTV was re-
stricted to the prostate +5-mm margin with avoidance of
the rectum. The low-dose PTV (margin of 10mm, 7mm
towards posterior) was covered by the 60Gy isodose. To
ensure precise application, an integrated offline/online pro-
tocol of volumetric cone beam CT-guided radiotherapy was
strictly implemented at our institution [11, 27–30]. Accurate
positioning with daily IGRT contributes to improved tumor
control and minimizes dose deviations [31–33], which is
especially important for small PTV margins in high-risk
disease with possible microscopic extracapsular extension
[34]. Our patient distribution is comparable to the Aus-
trian-German dose-escalation trial (74Gy for intermediate-
and high-risk patients) published by Goldner et al. using
3D conformal radiotherapy [35]: while GU and GI toxicity
(grade ≥2) were higher (34 and 30%), 5-year bRFS seemed
inferior (80% intermediate, 60% high risk) to our study.
This underlines both the importance of technical advances
(IMRT and IGRT) and of high effective doses.
Wortel et al. [36] compared the conventionally fraction-
ated 78-Gy arms from two randomized consecutive Dutch
trials using identical toxicity scoring. IG-IMRT compared
to conventional 3D treatment led to a statistically signifi-
cant reduction of GI toxicity ≥2 from 37.6 to 24.9%. There
was at best a trend concerning GU toxicity ≥2 (36.4% vs.
46.2%). This is well in line with our results. Dose modu-
lation using an integrated boost for the gross prostate with
a tight margin may have further reduced relevant side ef-
fects.
Late GU and GI toxicity peaked between the 36-month
to 60-month follow-up period consistent with earlier re-
ports [11, 37]. We observed a late grade 3 GU toxicity rate
of 4.0% and a cumulative GU toxicity ≥2 rate of 26.3% at
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5 years after treatment, which seems promising consider-
ing a prescribed EQD2> 80Gy. Relevant structures at risk
(urethra and bladder base) are always part of the anatomi-
cal CTV. Comparisons to the literature remain challenging,
as particularly the reported GU toxicity rates differ consid-
erably (grade ≥2, for example, 41.3% in the HYPRO trial
[38], 29.7% RTOG 0415 trial [4], 22.2% PROFIT trial [19],
12.8% CHHIP trial [2], and 26.3% GETUG 06 trial (80Gy)
[39]). The prevalence of lower urinary tract symptoms in-
creases in an ageing population and may influence reporting
of long-term toxicity [40]. Prophylactic lymph node irradi-
ation in 26.3% (n= 91) of our patients seemed to have an
increased risk of GU toxicity in our series as well as in
other trials [26, 41]. Overall, only 1.2% of the patients ex-
perienced late grade 3 GI toxicity and the cumulative late
GI toxicity grade ≥2 rate of 12.1% remains favorable com-
pared to randomized trials of hypofractionated radiotherapy
(for example, Catton et al. 8.9% [19], Dearnarly et al. 14.7%
[2], and Aluwini et al. 21.9% [38]). A low GI toxicity rate
is likely attributed to our institutional policy to avoid an
overlap between the organ at risk rectum and PTVBoost and
the definition of strict constraints for the posterior rectal
wall to further limit rectal toxicity. This zero margin for
the high-dose volume approach theoretically bears the risk
of underdosage of dominant index lesions in the peripheral
zone, but adequate dose coverage was demonstrated in an
earlier publication [12].
Although dose escalation above 80Gy might not fur-
ther increase biochemical control in moderately hypofrac-
tionated radiotherapy [42], new emerging techniques aim
at improving prostate cancer treatment: the ASCENDE-RT
trial impressively showed a high rate of biochemical con-
trol, despite a high proportion of high-risk patients, at the
cost of increased toxicity by adding LDR brachytherapy to
external beam radiotherapy [43]. Another recent approach
is dose escalation to the dominant index lesion as examined
in the FLAME-trial. Although outcome data are pending,
the published toxicity rates are promising [10]. Further-
more, recent publications of phase 3 trials [5, 6] of ultra-
hypofractionated regimes [44] report encouraging outcome
and toxicity data with application of precise position veri-
fication systems (fiducial markers and/or catheter demarca-
tion of the urethra) and intrafractional motion monitoring.
Randomized trials are needed for the comparison of mod-
erately hypofractionated radiotherapy with the abovemen-
tioned techniques to find the best therapeutic ratio.
Conclusion
Moderately hypofractionated dose-escalated prostate radio-
therapy using an integrated boost concept with no rectal
margin for the high-dose PTV was safe and achieved high
rates of long-term biochemical control and survival. De-
spite dose escalation, cone beam CT-based image-guided
radiotherapy accomplished low rates of long-term toxicity,
especially of gastrointestinal toxicity. Androgen deprivation
in high-risk disease contributed to biochemical control.
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